Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test

Kenny, Louise C., Thomas, Grégoire, Poston, Lucilla, Myers, Jenny E., Simpson, Nigel A. B., McCarthy, Fergus P., Brown, Leslie W., Bond, Alison E., Tuytten, Robin and Baker, Philip N. and Screening for Pregnancy Endpoints Consortium (2020) Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test. PLoS One, 15 (12). ISSN 1932-6203

Preview

PDF (Prediction of preeclampsia risk in first time pregnant women- Metabolite biomarkers for a clinical test) - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality. Accurate prediction of preeclampsia risk would enable more effective, risk-based prenatal care pathways. Current risk assessment algorithms depend on clinical risk factors largely unavailable for first-time pregnant women. Delivering accurate preeclampsia risk assessment to this cohort of women, therefore requires for novel biomarkers. Here, we evaluated the relevance of metabolite biomarker candidates for their selection into a prototype rapid, quantitative Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) based clinical screening assay. First, a library of targeted LC-MS/MS assays for metabolite biomarker candidates was developed, using a medium-throughput translational metabolomics workflow, to verify biomarker potential in the Screening-for-Pregnancy-Endpoints (SCOPE, European branch) study. A variable pre-selection step was followed by the development of multivariable prediction models for pre-defined clinical use cases, i.e., prediction of preterm preeclampsia risk and of any preeclampsia risk. Within a large set of metabolite biomarker candidates, we confirmed the potential of dilinoleoyl-glycerol and heptadecanoyl-2-hydroxysn- glycero-3-phosphocholine to effectively complement Placental Growth Factor, an established preeclampsia biomarker, for the prediction of preeclampsia risk in first-time pregnancies without overt risk factors. These metabolites will be considered for integration in a prototype rapid, quantitative LC-MS/MS assay, and subsequent validation in an independent cohort.

Item Type:	Article
Additional Information:	Publisher Copyright: © 2020 Kenny et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Uncontrolled Keywords:	general ,/dk/atira/pure/subjectarea/asjc/1000
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Related URLs:	http://www.scopus.com/inward/record.url?...
Depositing User:	LivePure Connector
Date Deposited:	24 Jun 2025 15:30
Last Modified:	24 Jun 2025 16:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/99705
DOI:	10.1371/journal.pone.0244369

Downloads

Actions (login required)

View Item